Nipah Virus Treatment: Antivirals, Antibodies, and Care

No drug or vaccine has been approved to treat or prevent Nipah virus infection. Management today relies on intensive supportive care, with a handful of investigational therapies showing promise in animal models and very early human trials. The case fatality rate across outbreaks has ranged from roughly 40 percent to 75 percent, and the virus is recognized as having pandemic potential, which has pushed researchers to fast-track candidates through the pipeline even though the sporadic, unpredictable nature of outbreaks makes conventional clinical trials exceptionally difficult.

Supportive Care Is Still the Foundation

When someone is admitted with suspected or confirmed Nipah virus disease, the immediate clinical response is supportive: intravenous fluids, mechanical ventilation if respiratory failure develops, anticonvulsants for seizures, and standard intensive-care protocols for multi-organ dysfunction. There is no specific antiviral regimen that doctors can prescribe with confidence, so the goal is to keep the patient alive long enough for the immune system to mount a response.¹ Severe cases frequently involve encephalitis, which means swelling in the brain, and this is what drives much of the mortality. Patients who do survive acute infection can be left with lasting neurological deficits.

During outbreaks, clinicians have sometimes used drugs like ribavirin or remdesivir on a compassionate-use basis, meaning the drugs are given without formal regulatory approval because no better option exists. This practice creates a tricky paradox: once a drug becomes the informal “standard of care” during an outbreak, it becomes harder to run a proper trial comparing it against a placebo, because withholding a treatment people already expect feels ethically fraught, even if the drug’s benefit has never been rigorously confirmed.²

Ribavirin and the Limits of Early Evidence

Ribavirin, a broad-spectrum antiviral that has been used against several RNA viruses, was the first drug tried against Nipah in a clinical setting. During the 1998-1999 Malaysian outbreak, an open-label trial gave ribavirin to 140 patients. Mortality in the treated group was about 32 percent compared with 54 percent among untreated controls, a reduction of roughly 36 percent.³ That sounds encouraging, but the trial was not randomized or blinded: the control group consisted of patients who were managed before ribavirin became available or who refused the drug, so the two groups may not have been comparable in severity or timing.

Animal studies have been less encouraging. In hamsters and monkeys infected with Nipah or the closely related Hendra virus, ribavirin delayed death at some doses but did not prevent it. At very high doses it caused toxic effects severe enough to require euthanasia in some animals.⁴ So while ribavirin has not been ruled out entirely, the preclinical picture is weak, and the one human dataset is far from definitive. It continues to be administered during outbreaks largely because options are so limited.

Remdesivir Shows Stronger Animal Data

Remdesivir, which became widely known during the COVID-19 pandemic, is a nucleotide prodrug that interferes with the machinery viruses use to copy their genetic material. It has shown the most consistent survival benefit in Nipah-infected primates of any small-molecule antiviral tested so far. In an early study, all four monkeys that received daily intravenous remdesivir starting 24 hours after a lethal Nipah challenge survived, while all untreated control animals died. Two of the treated monkeys showed mild respiratory signs, but none developed severe disease.⁵

The catch is timing. When treatment was delayed until three days after infection, the picture was less clean. About two-thirds of monkeys in the high-dose group survived, but none were spared clinical disease entirely, and survivors still showed brain lesions at necropsy.⁶ That is a recurring theme in Nipah treatment research: even the most promising drugs lose potency rapidly as the window between infection and treatment widens. In the real world, many patients do not present to a hospital until several days into the illness, which is a serious practical limitation for any therapy that works best early.

A systematic review of all Nipah therapeutics concluded that remdesivir and a monoclonal antibody called m102.4 are currently the only two candidates with enough evidence to justify advancing to clinical trials, either alone or in combination.⁷

Favipiravir and Molnupiravir as Oral Alternatives

Two other antivirals deserve mention because they could potentially be given by mouth, which would be a huge advantage in rural outbreak settings where intravenous infusions are impractical. Favipiravir, another nucleoside analogue prodrug, reduced Nipah virus replication in cell culture at moderate concentrations and, in one hamster study, completely protected animals when dosing started immediately after infection: all treated hamsters survived without clinical signs, while all controls died within five to six days.⁸ Lab work confirmed that henipaviruses are sensitive to favipiravir at concentrations consistent with those effective against other related viruses.⁹

Molnupiravir, which also saw use during COVID-19, works by introducing copying errors into the virus’s genome, producing less functional viral offspring. In a mouse model of viral encephalitis, oral molnupiravir reduced neurological disease development by about 31 percent when treatment started on the day of infection, and by about 23 percent when the virus was delivered through the nose.¹⁰ Those are modest numbers, and the work was done in mice rather than primates, so the evidence is much thinner than for remdesivir. Still, the convenience of oral dosing keeps both favipiravir and molnupiravir in the conversation.

The Monoclonal Antibody m102.4

If remdesivir is the leading small-molecule candidate, the monoclonal antibody m102.4 is its counterpart among biologic therapies. It is a fully human antibody that targets the G glycoprotein on the surface of both Nipah and Hendra viruses, blocking the step where the virus attaches to host cells.¹¹ In primate studies, the results have been striking. Twelve monkeys given two doses of m102.4 after a lethal Nipah infection all survived, even when the first dose was delayed until five days post-infection. Untreated control animals died between days eight and ten.¹²

There is an important caveat involving viral strains. Those early primate studies used the Malaysia strain of Nipah virus. When the same treatment schedule was tested against the Bangladesh strain, which is responsible for most recent human outbreaks and tends to be more lethal, the effective treatment window shrank considerably. Animals treated within three days survived, but those treated on days five and seven did not fare better than untreated controls.¹³ This narrower window for the Bangladesh strain makes early diagnosis even more critical.

A phase 1 safety trial of m102.4 in healthy human volunteers has been completed, and the antibody was well tolerated.¹⁴ But no efficacy trial in actual Nipah patients has been conducted yet.

Newer Antibody Candidates

Researchers have not stopped at m102.4. A second wave of monoclonal antibodies is being explored, including some that target the virus’s F (fusion) glycoprotein rather than its G (attachment) glycoprotein. The F protein is what drives the actual merging of viral and host-cell membranes after the virus has already latched on, so blocking it offers a complementary mechanism. One such antibody, hu1F5, was tested head-to-head against m102.4 in monkeys challenged with Nipah. Both provided protection, and the study established that hu1F5 outperformed another F-targeting antibody called hu12B2 in a hamster model, earning its spot in the primate comparison.¹⁵

Having antibodies that target two different viral proteins opens the door to combination therapy, the same logic that revolutionized HIV treatment. If one antibody’s target mutates, the other may still work. This approach has not been tested in Nipah-infected primates yet, but it is a clear next step.

Why the Virus Is Hard to Block

To understand why treatment is so challenging, it helps to know a little about how Nipah gets into cells. The virus uses its G glycoprotein to grab onto human proteins called ephrin-B2 and ephrin-B3 on the cell surface.¹⁶ These ephrin proteins are found on cells lining blood vessels, in the lungs, and throughout the brain, which is why Nipah causes such widespread damage. Once the G protein has latched on, the F protein is activated and fuses the viral membrane with the host cell, releasing the virus’s genetic payload inside.¹⁷

This entry mechanism is important because it defines the therapeutic targets. Drugs or antibodies that block the G-ephrin interaction (like m102.4) prevent attachment. Drugs that block F activation (like hu1F5) prevent fusion. And nucleotide analogues like remdesivir disrupt the copying of viral RNA after the virus is already inside the cell. Each strategy has a different window of usefulness, and none works well once the virus has spread widely through the body and into the brain, where drug penetration is poor. The blood-brain barrier, which protects the brain from many circulating substances, also keeps most therapeutics out.

Mutations in the G and F proteins add another layer of uncertainty. Computational analyses have identified specific mutations that change how tightly the virus binds to ephrin-B2, potentially affecting how well current antibodies will work against future viral variants.¹⁸

Strain Differences Complicate Everything

Nipah virus exists in at least two recognized genotypes: the Malaysia strain (NiV-M), responsible for the original 1998-1999 outbreak, and the Bangladesh strain (NiV-B), which has caused recurring outbreaks in Bangladesh and India since 2001. These strains do not behave identically, and the differences matter for treatment.

In monkey studies using aerosolized virus, NiV-B caused a 75 percent fatality rate and was marked by rapid respiratory decline, while NiV-M caused a 27 percent fatality rate and was more associated with brain inflammation and blood vessel damage.¹⁹ Survivors of NiV-M infection mounted stronger antibody responses than NiV-B survivors, who showed weaker and delayed immune reactions. In hamster studies, the Bangladesh strain showed somewhat different dose-lethality patterns by exposure route, with intranasal NiV-B being less lethal at a given dose than NiV-M administered the same way.²⁰

The practical concern is that most animal testing of therapeutics has been done with one strain or the other, not both. The narrower treatment window for m102.4 against NiV-B compared to NiV-M, mentioned earlier, is a concrete example of how strain choice can change the conclusions. Any therapy advancing toward human use will need to demonstrate efficacy against NiV-B specifically, since that is the strain currently circulating in human populations.

Vaccines in the Pipeline

Prevention would obviously be preferable to treatment, and several vaccine candidates are moving through development. A subunit vaccine based on the soluble G glycoprotein of Nipah virus induced both antibody and T-cell responses in mice and pigs and provided protection against pseudovirus challenge in mice.²¹ A viral-vector vaccine using a related approach (the Hendra virus G protein in a vesicular stomatitis virus backbone) has been used to vaccinate horses in Australia against Hendra and is being explored for human Nipah protection as well.

mRNA technology, refined during the COVID-19 response, has entered the Nipah space. Moderna’s mRNA-1215 vaccine, which encodes modified versions of both the pre-fusion F protein and the G protein, completed a phase 1 trial in healthy adults. The vaccine was well tolerated, produced neutralizing antibodies within two weeks of the first dose, and those antibody levels remained elevated for at least a year after a booster.²² A separate research group has designed an mRNA vaccine that encodes a 60-unit nanoparticle displaying Nipah G protein domains, which triggered strong neutralizing antibody responses in preclinical testing.²³

None of these vaccines are close to licensure. The fundamental problem is the same one that plagues therapeutic trials: Nipah outbreaks are small, geographically confined, and unpredictable, so enrolling enough participants for a large efficacy trial is extraordinarily difficult. Regulators may ultimately need to rely on the “Animal Rule,” which allows approval based on animal efficacy data plus human safety data when traditional trials are not feasible.

Relapsing and Late-Onset Encephalitis

Even survivors of acute Nipah infection are not necessarily in the clear. During follow-up of Malaysian outbreak survivors, about 7.5 percent of those who had acute encephalitis experienced a relapse, and about 3.4 percent of people who initially had only mild or no neurological symptoms developed late-onset encephalitis months later. The average interval was about eight months after the original infection. Common features included fever, headache, seizures, and focal neurological signs, and about 18 percent of those with relapsing or late-onset encephalitis died.²⁴

Autopsy findings from these patients showed evidence of active viral infection in the brain, and primate research has confirmed that Nipah virus can persist in the central nervous system of survivors long after the acute illness resolves.²⁵ This persistence raises a difficult question for treatment development: even if a drug clears the virus from the blood and lungs, will it reach viral reservoirs in the brain? None of the leading therapeutic candidates have been evaluated for their ability to prevent relapsing encephalitis, and the long delay between initial infection and relapse makes it unclear how long treatment or monitoring would need to continue.

Why Trials Are So Hard to Run

Nipah outbreaks tend to involve small clusters of cases, often in remote areas of Bangladesh or the Indian state of Kerala. A typical outbreak may produce fewer than two dozen confirmed cases before it burns out. That makes the kind of large, randomized trial used to evaluate drugs for common diseases nearly impossible. A systematic review noted that no therapeutics or vaccines have been licensed to date and that only a few candidates are far enough along in development to justify attempting a clinical trial at all.²⁶

There are ways to work around these constraints. Adaptive trial designs, where the protocol evolves as data accumulate across multiple outbreaks over years, can pool small numbers of patients. Ring-vaccination strategies, borrowed from Ebola response playbooks, could test a vaccine in contacts of confirmed cases rather than in the general population. And the Animal Rule pathway, mentioned above, offers a regulatory route that does not require thousands of human participants. But each of these workarounds has limitations, and the practical reality is that the world may face another severe Nipah outbreak before any treatment has been formally validated.

CRISPR Screens and the Search for Host Targets

A more speculative line of research involves identifying human genes that viruses need in order to infect cells, then designing drugs that interfere with those human targets rather than viral ones. Genome-wide CRISPR screens have already been used to map host factors essential for coronaviruses, knocking out genes one at a time in cell culture and seeing which knockouts make cells resistant to infection.²⁷ The same approach is being applied to paramyxoviruses, the broader family that includes Nipah. In theory, a drug that blocks a host factor shared across several virus families could serve as a broad-spectrum antiviral, useful against Nipah and other emerging threats. In practice, interfering with a human protein carries a higher risk of side effects than targeting a viral protein, so any host-directed therapy would need careful safety profiling. This research is still at the discovery stage, years from producing a drug candidate, but it represents one of the more creative avenues being explored.

What Combination Therapy Might Look Like

Given the distinct mechanisms of the leading candidates, researchers have discussed combining a monoclonal antibody with a small-molecule antiviral. The logic is straightforward: m102.4 blocks the virus from entering new cells, while remdesivir sabotages the replication machinery inside already-infected cells. Used together, they could in principle attack the infection from two angles, potentially widening the treatment window that is so narrow with either drug alone. No published primate study has tested this combination yet, but the systematic review that prioritized candidates for clinical trials flagged the combination of m102.4 and remdesivir as the most trial-ready regimen for both prophylaxis and early treatment. Whether the combination would be additive, synergistic, or merely logistically complicated remains to be seen.

The logistics are not trivial. Both m102.4 and remdesivir currently require intravenous administration, which demands clinical infrastructure that may not exist at the point of first patient contact in rural South Asia. The development of oral antivirals like favipiravir could fill that gap, allowing initial treatment in the field before a patient can be transferred to an intensive care unit. A staged approach, oral antiviral started immediately, monoclonal antibody added when hospital care begins, has been discussed in the literature but has not been formalized into a treatment protocol.